Study of adjuvant chemotherapy in osteogenic sarcoma.
Twelve patients with osteosarcoma but without metastases were treated with adjuvant chemotherapy following surgical amputation for the primary lesion. The chemotherapy regimen utilized vincristine, actinomycin D, and cyclophosphamide (in high pulse doses) administered intermittently over a 55-week period. Four of the 12 patients (33%) are surviving with no evidence of disease 54 months or longer from time of surgery. These results suggest that the 3-drug combination used in this study should be considered in the formulation of future multidrug adjuvant chemotherapy programs in the management of patients with osteosarcoma.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003609:Dactinomycin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide